About Kawin


  • 2017-05-31KW-136 in Combination with Sofosbuvir Under Phase 3 Trial

    In May 2017, Kawin Technology initiated a phase 3 trial program to investigate use of KW-136, an investigational DAA against HCV, in combination with sofosbuvir for treatment of pan-genotypic HCV infection. This regimen is expected to provide the first-in...

  • 2017-04-14 Long-acting Interferon Granted Priority Review

    On April 13th, 2017, China Food and Drug Administration (CFDA) Center for Drug Evaluation (CDE) announced the fifteenth batch of candidates for new drug applications and their applicants. Among these applicants, Kawin Technology has its classification 1 p...

  • 2015-07-23Kawin Technology passes Columbia INVIMA GMP Recheck

    Five years ago, two production lines, biochemical products injection and pharmaceutical preparation has acquired INVIMA GMP certificates. During these years, Kawin Technology experienced both local and foreign GMP checks, and successfully passed China GMP...

  • 2015-07-23Kawin Technology becomes G20 Engineering Corporation

    Kawin Technology was chosen as Beijing Biochemical Spanning Development Engineering Corporation (G20). G20 Engineering is implemented as Beijing Technology project, aimed at promoting the transition of biochemical production from strategy emerging industr...